मूलभूत आँकड़े
| LEI | 529900MX6XCNZC7MM155 |
| CIK | 1595097 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Corbus Pharmaceuticals Holdings, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| August 5, 2025 |
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Exhibit 99.1 Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update • Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025 • Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913 • All three clinical programs (CRB-701, CRB-913, CRB-601) on track for data readouts in the second half of 2025 Norwoo |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) ( |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| May 6, 2025 |
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update Exhibit 99.1 Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update • Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumors • SAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1 inverse agonist CRB-913 • Dose escalation study on schedule for |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| March 18, 2025 |
Exhibit 10.1 This Agreement is made on March 15, 2025 Between: (1) Corbus International Limited (company number: 11195935) whose registered office is at 5 New Street Square, London, EC4A 3TW (Company, we, us); and (2) Ian Hodgson of , , (You, your) It is agreed as follows: 1. Definitions and interpretation 1.1 This Agreement means this agreement and any schedules to this agreement which form part |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| March 11, 2025 |
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update Appendix 99.1 Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update • CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study • Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancer • CRB 913 SAD/MAD obesity study expected to start in March 2025 • $149m of cash & investments as of December 31,20 |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number 001-37348 Corbus Pharma |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| March 11, 2025 |
List of Subsidiaries of the Company.* Exhibit 21.1 SUBSIDIARIES (WHOLLY-OWNED) OF CORBUS PHARMACEUTICALS HOLDINGS, INC. Name of Organization Jurisdiction Corbus Pharmaceuticals, Inc. Delaware Corbus International Limited United Kingdom Corbus Pharmaceuticals Australia Pty Ltd Australia |
|
| March 11, 2025 |
Exhibit 19.1 CORBUS PHARMACEUTICALS HOLDINGS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES* Two copies of this Statement of Company Policy on Insider Trading and Policy Regarding Special Trading Procedures (collectively, this “Policy”) are being provided to you. You should read this Policy, address questions to Sean Moran, our Chief Financial |
|
| February 14, 2025 |
EXHIBIT A: Joint Filing Agreement EX-99.A 2 ss4343261ex99a.htm JOINT FILING AGREEMENT CUSIP No. 21833P301 SCHEDULE 13G Page 9 of 9 Pages EXHIBIT A: Joint Filing Agreement The undersigned hereby agree that this Amendment No. 1 to the Statement on Schedule 13G, dated December 31, 2024 (this “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Corbus Pharmaceuticals Holdings, Inc. is filed on behalf of e |
|
| February 14, 2025 |
Exhibit 99.1 CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 • Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 • Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study • Low levels of peripheral |
|
| February 14, 2025 |
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation February 14, 2025 Exhibit 99. |
|
| February 14, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| December 3, 2024 |
Exhibit 99.1 FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer Norwood, MA, December 3, 2024 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administration (FDA) has granted F |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 03, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| November 14, 2024 |
CRBP / Corbus Pharmaceuticals Holdings, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 cormorant-crbp093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 21833P301 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 14, 2024 |
SC 13G 1 ss4113323sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 21833P301 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 14, 2024 |
SC 13G/A 1 crbp1015240sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 21833P301 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This S |
|
| November 14, 2024 |
SC 13G/A 1 ef20038297sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value, $0.0001 per share (Title of Class of Securities) 21833P301 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of |
|
| November 14, 2024 |
SC 13G/A 1 p24-3154sc13ga.htm CORBUS PHARMACEUTICALS HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 21833P301 (CUSIP Number) September 30, 2024 (Date of Event Which Requi |
|
| November 12, 2024 |
SC 13G/A 1 p24-3024sc13ga.htm CORBUS PHARMACEUTICALS HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 21833P301 (CUSIP Number) September 30, 2024** (Date of Event Which Req |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| November 7, 2024 |
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update Exhibit 99.1 Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update • Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701) - First data expected to be presented in Q1 2025 • Presented New CRB-913 Pre-Clinical Data at Obesity Week 2024 - Phase 1 Trial Expected to Commence in Q1 2025 |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| November 7, 2024 |
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation November 7, 2024 Exhibit 99. |
|
| November 4, 2024 |
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 Exhibit 99.1 Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 • CRB-913 brain levels are 15-fold lower than monlunabant in lean mice • Dose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO mice • Semaglutide treatment followed by its replacement with CRB-913 demonstrated continued weight loss in DIO mice • Switching fro |
|
| November 4, 2024 |
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation November 4, 2024 Exhibit 99. |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 04, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| October 15, 2024 |
CRBP / Corbus Pharmaceuticals Holdings, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 CRBPSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) CORBUS PHARMACEUTICALS HOLDINGS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 21833P301 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) |
|
| October 11, 2024 |
CRBP / Corbus Pharmaceuticals Holdings, Inc. / Octagon Capital Advisors LP Passive Investment SC 13G 1 crbp1011241sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 21833P301 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check t |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporatio |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporatio |
|
| August 20, 2024 |
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung Exhibit 99.1 Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung Norwood, MA, August 20, 2024 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committ |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| August 6, 2024 |
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Exhibit 99.1 Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update • Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancer • CRB-701 Phase 1 dose escalation underway in USA and Europe for patients with metastatic urothelial can |
|
| August 6, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporatio |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporatio |
|
| August 6, 2024 |
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation August 6, 2024 Exhibit 99. |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| June 3, 2024 |
Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation June 1, 2024 Exhibit 99. |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| June 3, 2024 |
Exhibit 99.1 SYS6002 (CRB-701) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 • An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy • SYS6002 (CRB-701) demons |
|
| May 31, 2024 |
CORBUS PHARMACEUTICALS HOLDINGS, INC. 2024 EQUITY COMPENSATION PLAN Exhibit 10.1 CORBUS PHARMACEUTICALS HOLDINGS, INC. 2024 EQUITY COMPENSATION PLAN 1. Establishment and Purpose 1.1 The purpose of the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Compensation Plan (the “Plan”) is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in th |
|
| May 31, 2024 |
As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No. |
|
| May 31, 2024 |
Calculation of Filing Fee Table.* Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Corbus Pharmaceuticals Holdings, Inc. |
|
| May 20, 2024 |
Form of Incentive Stock Option Grant Agreement. EXHIBIT 10.2 FORM OF INCENTIVE STOCK OPTION GRANT AGREEMENT CORBUS PHARMACEUTICALS HOLDINGS, INC. This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the |
|
| May 20, 2024 |
EXHIBIT 10.3 FORM OF NONQUALIFIED STOCK OPTION GRANT AGREEMENT CORBUS PHARMACEUTICALS HOLDINGS, INC. This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto ( |
|
| May 20, 2024 |
Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Compensation Plan. EXHIBIT 10.1 CORBUS PHARMACEUTICALS HOLDINGS, INC. 2024 EQUITY COMPENSATION PLAN 1. Establishment and Purpose 1.1 The purpose of the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Compensation Plan (the “Plan”) is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in th |
|
| May 20, 2024 |
EXHIBIT 10.5 FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT CORBUS PHARMACEUTICALS HOLDINGS, INC. 2024 EQUITY INCENTIVE PLAN This Restricted Stock Unit Award Agreement (the “Agreement” or “Award Agreement”), dated as of the “Award Date” set forth in the attached Exhibit A, is entered into between Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and the individual named |
|
| May 20, 2024 |
EXHIBIT 10.4 FORM OF Restricted Stock Agreement CORBUS PHARMACEUTICALS HOLDINGS, INC. This Restricted Stock Award Agreement (the “Agreement”), dated as of the “Award Date” set forth in the attached Exhibit A (the “Award Date”), is entered into between Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Awardee”). WHEREAS |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| May 7, 2024 |
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update • Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 • $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 • Appointed Dr. Dominic Smethurst as Chief Medical Officer Norwood, MA, May 7, 2024 (GLOBE NEWSWIRE) - Corbus Pharmaceutic |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 10, 2024 |
Exhibit 10.1 FIFTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Fifth Amended and Restated Employment Agreement (this “Agreement”), effective as of April 10, 2024 (the “Effective Date”), is between Corbus Pharmaceuticals Holdings, Inc. (the “Company”) and Yuval Cohen (the “Executive”). WITNESSETH: WHEREAS, the Executive has been employed by the Company as its Chief Executive Officer pursuant to |
|
| April 10, 2024 |
Exhibit 10.2 SIXTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SIXTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), effective as of April 10, 2024 (the “Effective Date”), is between Corbus Pharmaceuticals Holdings, Inc. (the “Company”) and Sean Moran (the “Executive”). WITNESSETH: WHEREAS, the Executive has been employed by the Company as its Chief Financial Officer pursuant to t |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 20, 2024 |
Up to $150,000,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-277888 PROSPECTUS Up to $150,000,000 Common Stock We have entered into an Open Market Sale Agreement, or sale agreement, with Jefferies LLC relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sale agreement, we may offer and sell shares of our common stock having an aggregate offering price of |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number 001 |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 21833P301 (CUSIP Number) March 8, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| March 18, 2024 |
Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062 Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062 March 18, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Corbus Pharmaceuticals Holdings, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-277888) Ladies and Gentlemen: In accordance with Rule 461 under the |
|
| March 13, 2024 |
Form of Subordinated Note (included in Exhibit 4.6).* Exhibit 4.6 CORBUS PHARMACEUTICALS HOLDINGS, INC., as Issuer and ●, as Trustee INDENTURE Dated as of ● Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between CORBUS PHARMACEUTICALS HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapp |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024 As filed with the Securities and Exchange Commission on March 13, 2024 Registration No. |
|
| March 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Corbus Pharmaceuticals Holdings, Inc. |
|
| March 13, 2024 |
Form of Senior Note (included in Exhibit 4.5).* Exhibit 4.5 CORBUS PHARMACEUTICALS HOLDINGS, INC., as Issuer and ●, as Trustee INDENTURE Dated as of ● Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between CORBUS PHARMACEUTICALS HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicabl |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number 001-37348 Corbus Pharma |
|
| March 12, 2024 |
Exhibit 10.33 This Agreement is made on February 27, 2024 Between: (1) Corbus International Limited (company number: 11195935) whose registered office is at 5 New Street Square, London, EC4A 3TW (Company, we, us); and (2) Dominic Smethurst of , , (You, your) It is agreed as follows: 1. Definitions and interpretation 1.1 This Agreement means this agreement and any schedules to this agreement which |
|
| March 12, 2024 |
List of Subsidiaries of the Company.* Exhibit 21.1 SUBSIDIARIES (WHOLLY-OWNED) OF CORBUS PHARMACEUTICALS HOLDINGS, INC. Name of Organization Jurisdiction Corbus Pharmaceuticals, Inc. Delaware Corbus International Limited United Kingdom Corbus Pharmaceuticals Australia Pty Ltd Australia |
|
| March 12, 2024 |
Exhibit 99.1 Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update • Encouraging CRB-701 (SYS6002) First-in Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 • IND Application for CRB-601 cleared; Ph1 study on track to commence in Summer of 2024 • Pre-clinical data for CRB-913 pres |
|
| March 12, 2024 |
Compensation Recovery Policy.* † EXHIBIT 97.1 CORBUS PHARMACEUTICALS HOLDINGS, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on November 8, 2023) 1. Purpose Corbus Pharmaceuticals Holdings, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Comp |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| February 28, 2024 |
CRBP / Corbus Pharmaceuticals Holdings, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 CRBPSC13G2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 21833P301 (CUSIP Number) FEBRUARY 23, 2024 (Date of event which requires filing of this statement) Check the appropria |
|
| February 14, 2024 |
EX-99.1 2 tm245955d11ex-1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Corbus Pharmaceuticals Holdings, In |
|
| February 14, 2024 |
SC 13G/A 1 ef20021584sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value, $0.0001 per share (Title of Class of Securities) 21833P301 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of t |
|
| February 14, 2024 |
SC 13G 1 tm245955d11sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 21833P301 (CUSIP Number) January 26, 2024 (Date of Event Which Requires Filing of this sta |
|
| February 14, 2024 |
SC 13G 1 ef20021583sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value, $0.0001 per share (Title of Class of Securities) 21833P103 (CUSIP Number) October 25, 2022 (Date of Event Which Requires Filing of this Sta |
|
| February 12, 2024 |
SC 13G 1 tm245429d27sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 21833P301 (CUSIP Number) February 2, 2024 (Date of Event Which Requires Filing of this Sta |
|
| February 12, 2024 |
EX-99.1 2 tm245429d27ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 12, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| February 12, 2024 |
SC 13G 1 p24-0742sc13g.htm CORBUS PHARMACEUTICALS HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 21833P301 (CUSIP Number) February 2, 2024 (Date of Event Which Requires Fili |
|
| February 9, 2024 |
SC 13G 1 CRBPSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 21833P301 (CUSIP Number) JANUARY 31, 2024 (Date of event which requires filing of this statement) Check the appropriate bo |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 02, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| February 5, 2024 |
Connecting Innovation to Purpose Corporate Presentation February 2, 2024 NASDAQ: CRBP • CorbusPharma. |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 21833P301 (CUSIP Number) January 26, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 5, 2024 |
SC 13G 1 tm244976d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 21833P301 (CUSIP Number) January 26, 2024 (Date of Event Which Requires Filing of this stat |
|
| February 5, 2024 |
EX-99.1 2 tm244976d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Corbus Pharmaceuticals Holdings, Inc. |
|
| February 5, 2024 |
EX-99.1 2 exhibit99-1.htm Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 5, 2024, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a st |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdi |
|
| February 1, 2024 |
4,325,000 Shares of Common Stock Corbus Pharmaceuticals Holdings, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-272314 PROSPECTUS SUPPLEMENT (To Prospectus dated June 13, 2023) 4,325,000 Shares of Common Stock Corbus Pharmaceuticals Holdings, Inc. We are offering 4,325,000 shares of our common stock. The public offering price is $19.00 per share. Our common stock is listed on the Nasdaq Capital Market under the symbol “CRBP.” On January 31, 2024, the las |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporati |
|
| February 1, 2024 |
Corbus Pharmaceuticals Announces Pricing of Public Offering EXHIBIT 99.2 Corbus Pharmaceuticals Announces Pricing of Public Offering Norwood, MA, Jan. 31, 2024 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 |
|
| February 1, 2024 |
Corbus Pharmaceuticals Announces Proposed Public Offering EXHIBIT 99.1 Corbus Pharmaceuticals Announces Proposed Public Offering Norwood, MA, Jan. 30, 2024 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warran |
|
| February 1, 2024 |
Underwriting Agreement, dated January 31, 2024 EXHIBIT 1.1 4,325,000 Shares Corbus Pharmaceuticals Holdings, Inc. UNDERWRITING AGREEMENT January 31, 2024 Jefferies LLC 520 Madison Avenue New York, New York 10022 As Representative of the several Underwriters Ladies and Gentlemen: Introductory. Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 31, 2024 As filed with the Securities and Exchange Commission on January 31, 2024 Registration No. |
|
| January 31, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-272314 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not a |
|
| January 31, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Corbus Pharmaceuticals Holdings, Inc. |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporati |
|
| January 29, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 p24-0486exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing add |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporati |
|
| January 29, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Corbus Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 21833P301 (CUSIP Number) January 26, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 29, 2024 |
Corbus Pharmaceuticals Holdings, Inc. Up to $75,000,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-272314 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 13, 2023) Corbus Pharmaceuticals Holdings, Inc. Up to $75,000,000 Common Stock This prospectus supplement amends and supplements the information in our prospectus, dated June 13, 2023 (the “Prospectus”), filed pursuant to our registration statement on Form S-3 (File No. 333-272314) (the “Re |
|
| January 26, 2024 |
Connecting Innovation to Purpose Corporate Presentation January 26 2024 NASDAQ: CRBP • CorbusPharma. |
|
| January 26, 2024 |
US21833P3010 / CORBUS PHARMACEUTICALS HOLDINGS INC / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 26, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporati |
|
| January 26, 2024 |
Exhibit 99.1 CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024 • Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses • All assessable nectin-4 positive study participants wi |
|
| January 26, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Corbus Pharmaceuticals Holdings, Inc. and further agree to |
|
| January 9, 2024 |
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601) • CRB-601 is designed to block the activation of latent TGFβ in the tumor microenvironment • Phase 1 clinical study set to commence H1 2024 • Pre-clinical data presented demonstrates robust anti-tumor activity in solid tumor models Norwood, MA, January 9, 2024 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporati |
|
| November 14, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| November 14, 2023 |
Connecting Innovation to Purpose Corporate Presentation November 2023 NASDAQ: CRBP • CorbusPharma. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| November 7, 2023 |
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update • Data from dose escalation study for CRB-701, a Nectin-4 ADC to treat solid tumors, on track for release in early 2024 along with start of U.S./EU Study • IND Submission for CRB-601, an αvβ8 Monoclonal Antibody to treat solid tumors, on track for Q4 2023 • Pre-clinical data for CRB-913, |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporatio |
|
| August 8, 2023 |
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update • CRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U. |
|
| August 3, 2023 |
Connecting Innovation to Purpose Corporate Presentation August 2023 NASDAQ: CRBP • CorbusPharma. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporatio |
|
| June 13, 2023 |
Up to $16,800,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-272314 PROSPECTUS Up to $16,800,000 Common Stock We have entered into an Open Market Sale AgreementSM, or sale agreement, with Jefferies LLC relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sale agreement, we may offer and sell shares of our common stock having an aggregate offering price of |
|
| June 12, 2023 |
As filed with the Securities and Exchange Commission on June 12, 2023 S-3/A Table of Contents As filed with the Securities and Exchange Commission on June 12, 2023 Registration No. |
|
| June 7, 2023 |
Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062 Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062 June 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Corbus Pharmaceuticals Holdings, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-272314) Ladies and Gentlemen: In accordance with Rule 461 under the S |
|
| June 1, 2023 |
Form of Subordinated Note (included in Exhibit 4.6).* EX-4.6 Exhibit 4.6 CORBUS PHARMACEUTICALS HOLDINGS, INC., as Issuer and •, as Trustee INDENTURE Dated as of • Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between CORBUS PHARMACEUTICALS HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4 |
|
| June 1, 2023 |
EX-1.3 Exhibit 1.3 AMENDMENT NO. 1 TO OPEN MARKET SALE AGREEMENT May 31, 2023 This Amendment No. 1 (“Amendment No. 1”) amends that certain Open Market Sale Agreement, dated as of August 6, 2020 (the “Agreement”), by and between Corbus Pharmaceuticals Holdings, Inc. (the “Company”) and Jefferies LLC (the “Agent”). Defined terms used herein and not otherwise defined shall have the meaning assigned t |
|
| June 1, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Corbus Pharmaceuticals Holdings, Inc. |
|
| June 1, 2023 |
Form of Senior Note (included in Exhibit 4.5).* EX-4.5 Exhibit 4.5 CORBUS PHARMACEUTICALS HOLDINGS, INC., as Issuer and •, as Trustee INDENTURE Dated as of • Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between CORBUS PHARMACEUTICALS HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inap |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on May 31, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 31, 2023 Registration No. |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| May 9, 2023 |
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update • Company expanded precision oncology pipeline with in-licensing of CRB-701: a clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical Group • CRB-701 Phase 1 dose escalation study ongoing in patients with advanced solid tumors in China • Presented latest CRB-601 an |
|
| April 24, 2023 |
Exhibit 10.1 SEPARATION AND GENERAL RELEASE AGREEMENT This Separation and General Release Agreement (the “Agreement”) is between Craig Millian (“Millian”) and Corbus Pharmaceuticals Holdings, Inc. (“Company”), and memorializes the separation of Millian’s employment, including the severance he will receive if he (a) signs and returns this Agreement to the Company on April 14, 2023 (the “Separation |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporati |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 10, 2023 |
Calculation of Filing Fee Table.* Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Corbus Pharmaceuticals Holdings, Inc. |
|
| March 10, 2023 |
As filed with the Securities and Exchange Commission on March 10, 2023 Table of Contents As filed with the Securities and Exchange Commission on March 10, 2023 Registration No. |
|
| March 7, 2023 |
Exhibit 10.29 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. THE REDACTED TERMS HAVE BEEN MARKED WITH THREE ASTERISKS [***] EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), dated as of February 12, 2023 (the “Effective Date”), is entered i |
|
| March 7, 2023 |
Exhibit 4.10 DESCRIPTION OF CAPITAL STOCK The following is a summary of information concerning capital stock of Corbus Pharmaceuticals Holdings, Inc. (“us,” “our,” “we” or the “Company”) and certain provisions of our amended and restated certificate of incorporation, as amended, and amended and restated bylaws, as amended, currently in effect. This summary does not purport to be complete and is qu |
|
| March 7, 2023 |
Exhibit 3.1 |
|
| March 7, 2023 |
List of Subsidiaries of the Company.* Exhibit 21.1 SUSIDIARIES OF CORBUS PHARMACEUTICALS HOLDINGS, INC. Name of Organization Jurisdiction Corbus Pharmaceuticals, Inc. Delaware Corbus International Limited United Kingdom Corbus Pharmaceuticals Australia Pty Ltd Australia |
|
| March 7, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CORBUS PHARMACEUTICALS HOLDINGS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. (a) Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place, if any, within or without the United States which is fixed by the Board of Directors of the |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number 001-37348 Corbus Pharma |
|
| March 7, 2023 |
Exhibit 99.1 Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update • Company expands precision oncology pipeline with licensing of CRB-701, clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical Group • CRB-701 Phase 1 dose escalation ongoing in China in patients with advanced solid tumors • CRB-601 anti-αvβ8 mAb pro |
|
| March 7, 2023 |
Connecting Innovation to Purpose Corporate Presentation March 2023 NASDAQ: CRBP • CorbusPharma. |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| March 6, 2023 |
Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA Exhibit 99.1 Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA Norwood, MA, March 6, 2023 (PR NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company’s Board of Directors. “Dr. Ben is a distinguished oncology researcher a |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 09, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorpor |
|
| February 13, 2023 |
Connecting Innovation to Purpose Corporate Presentation February 2023 NASDAQ: CRBP • CorbusPharma. |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 09, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| February 13, 2023 |
EX-3 2 crbp-ex31.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CORBUS PHARMACEUTICALS HOLDINGS, INC. Corbus Pharmaceuticals Holdings, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: FIRST: The name of the Corporati |
|
| February 13, 2023 |
Exhibit 99.1 Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) • CRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumors • Clinical development is underway and will focus on urothelial cancer and other Nectin-4-positive solid tumors potentially includ |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 04, 2023 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporati |
|
| December 21, 2022 |
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update ? Latest pre-clinical data for CRB-601 monotherapy and in combination with anti-PD1 therapy to be presented this Thursday at SITC 2022 ? IND submission for CRB-601 is on track for mid-2023 ? Expanding oncology pipeline through strategic transactions remains key priority ? Cash and investm |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 31, 2022 |
Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) entered into as of October 25, 2022, by and among Corbus Pharmaceuticals, Inc., a Delaware corporation (?Borrower Representative?), and each other Person party thereto as a borrower from time to time (together with the Borrower Representative, collectively, ?Borrower |
|
| October 31, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporati |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4348039 (State or other jurisdiction of incorporation or organization) (IRS Employer Ident |
|
| October 12, 2022 |
Certificate of Designation of the Series A Preferred Stock of the Company, dated October 12, 2022. EX-3.2 3 crbp-ex32.htm EX-3.2 Exhibit-3.2 CORBUS PHARMACEUTICALS HOLDINGS, INC. CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by th |
|
| October 12, 2022 |
Exhibit-3.1 AMENDMENT NO. 2 TO THE AMENDED AND RESTATED BYLAWS OF CORBUS PHARMACEUTICAL HOLDINGS, INC. (the “Corporation”) Article I of the Amended and Restated Bylaws of Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation, as amended to date (the “Bylaws”), is hereby amended as follows: Article I, Section 5 of the Bylaws be, and hereby is, amended to read in its entirety as follows: “SE |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporati |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorpora |
|
| September 26, 2022 |
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors Norwood, MA, September 26, 2022 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 18)* Corbus Pharmaceuticals Holdings Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 21833P103 (CUSIP Number) August 23, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporatio |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| August 9, 2022 |
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy ? IND submission for CRB-601 is on track for mid-2023 ? Expanding immuno-oncology pipeline through strategic transactions remains key priority ? Cash an |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 06, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| June 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| June 8, 2022 | ||
| May 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation) |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| May 10, 2022 |
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Exhibit 99.1 Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update ? Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy ? IND submission for CRB-601 is on-track for the first half of 2023 ? Expanding immuno-oncology pipeline through strategic transactions remains key prior |
|
| April 15, 2022 |
Exhibit 10.3 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?), effective as of April 11, 2022 (the ?Effective Date?), is between Corbus Pharmaceuticals Holdings, Inc. (the ?Company?) and Craig Millian (the ?Executive?). WITNESSETH: WHEREAS, the Executive has been employed by the Company as its Chief Operating Officer pursuant |
|
| April 15, 2022 |
Exhibit 10.2 FIFTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT This FIFTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?), effective as of April 11, 2022 (the ?Effective Date?), is between Corbus Pharmaceuticals Holdings, Inc. (the ?Company?) and Sean Moran (the ?Executive?). WITNESSETH: WHEREAS, the Executive has been employed by the Company as its Chief Financial Officer pursuant to t |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| April 15, 2022 |
Exhibit 10.1 FOURTH AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Fourth Amended and Restated Employment Agreement (this ?Agreement?), effective as of April 11, 2022 (the ?Effective Date?), is between Corbus Pharmaceuticals Holdings, Inc. (the ?Company?) and Yuval Cohen (the ?Executive?). WITNESSETH: WHEREAS, the Executive has been employed by the Company as its Chief Executive Officer pursuant t |
|
| April 11, 2022 |
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting Norwood, MA, April 8, 2022 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. |
|
| April 11, 2022 | ||
| April 11, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 08, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| April 11, 2022 | ||
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 15, 2022 |
Calculation of Filing Fee Table.* Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Corbus Pharmaceuticals Holdings, Inc. |
|
| March 15, 2022 |
As filed with the Securities and Exchange Commission on March 15, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| March 8, 2022 |
List of Subsidiaries of the Company.* Exhibit 21.1 SUSIDIARIES OF CORBUS PHARMACEUTICALS HOLDINGS, INC. Name of Organization Jurisdiction Corbus Pharmaceuticals, Inc. Delaware Corbus International Limited United Kingdom Corbus Pharmaceuticals Australia Pty Ltd Australia |
|
| March 8, 2022 |
Exhibit 99.1 Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates ? Company is advancing its integrin program and on schedule for initiating clinical studies in 2023 ? Expanding immuno-oncology pipeline through strategic transactions remains key priority ? Cash and investments on hand of $98.3 million funds operations into the first quart |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number 001-37348 Corbus Pharma |
|
| March 8, 2022 |
Exhibit 10.31 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), effective as of December 6, 2021 (the ?Effective Date?), is between Corbus Pharmaceuticals Holdings, Inc. (the ?Company?) and Rachael Brake (the ?Executive?). WITNESSETH: WHEREAS, the Company desires to employ the Executive as its Chief Scientific Officer, and the Executive desires to accept such employment, on the te |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 08, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporation |
|
| March 8, 2022 |
Exhibit 4.10 DESCRIPTION OF CAPITAL STOCK The following is a summary of information concerning capital stock of Corbus Pharmaceuticals Holdings, Inc. (?us,? ?our,? ?we? or the ?Company?) and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws currently in effect. This summary does not purport to be complete and is qualified in its entirety by |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 17)* Corbus Pharmaceuticals Holdings Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 21833P103 (CUSIP Number) February 11, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| January 3, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 03, 2022 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporati |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37348 46-4348039 (State or Other Jurisdiction of Incorporat |
|
| November 12, 2021 |
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates Exhibit 99.1 Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates ? Company continues to advance integrin program from preclinical development toward the clinic ? Expanding pipeline through strategic transactions remains key priority ? Cash and investments on hand of $108 million sufficient to support execution of research, clinical and operational goa |
|
| September 28, 2021 |
Exhibit 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (the ?Amendment?) is made and entered into between Corbus Pharmaceuticals Holdings, Inc. (the ?Company?) and Craig Millian (the ?Executive?) effective as of September 27, 2021 (the ?Effective Date?). WHEREAS, Company and the Executive are parties to an Amended and Restated Employment Agreement dated |
|
| September 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2021 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37348 46-4348039 (State or other jurisdiction (Commission |
|
| September 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37348 46-4348039 (State or other jurisdiction of incorporat |
|
| September 22, 2021 |
Exhibit 10.1 SEPARATION AND GENERAL RELEASE AGREEMENT This Separation and General Release Agreement (the ?Agreement?) is between Barbara White (?White?) and Corbus Pharmaceuticals, Inc. (?Company?), and memorializes the separation of White?s employment, including the severance she will receive if she (a) signs and returns this Agreement to the Company on September 17, 2021 (the ?Separation Date?) |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37348 46-4348039 (State or other jurisdiction (Commission (IR |
|
| August 12, 2021 |
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates Exhibit 99.1 Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates ? Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinic ? Augmenting the pipeline through business development continues to be a priority ? Cash and investments on hand of |
|
| August 12, 2021 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. THE REDACTED TERMS HAVE BEEN MARKED WITH THREE ASTERISKS [***] LICENSE AGREEMENT This License Agreement (?Agreement?) is entered into and made effective as of May 25th, 2021 (?Effective Date?) by and between Mil |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| August 12, 2021 |
Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. THE REDACTED TERMS HAVE BEEN MARKED WITH THREE ASTERISKS [***] EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and CORBUS PHARMACEUTICALS, INC. for BLOCKING HUMANIZED ANTIBODIES T |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37348 46-4348039 (State or other jurisdiction (Commission (IR |
|
| August 12, 2021 |
EX-3.1 2 ex3-1.htm Exhibit 3.1 |
|
| July 22, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 |
|
| July 22, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37348 46-4348039 (State or other jurisdiction (Commission (IRS |
|
| June 24, 2021 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37348 46-4348039 (State or other jurisdiction of incorporation) |
|
| June 24, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Corbus Pharmaceuticals Announces Topline Results from determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis ● Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28 ● Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on the dermatomyositis subtype ● Lenabasu |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37348 46-4348039 (State or other jurisdiction (Commission (IRS |
|
| June 17, 2021 |
Certificate of Amendment of the Certificate of Incorporation, as amended, dated June 17, 2021 Exhibit 3.1 |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37348 46-4348039 (State or other jurisdiction (Commission (IRS E |
|
| June 1, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases ● Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ ● High potency anti- αvβ8 mAb licensed from University of California San Francisco and anti- αvβ6/ αvβ8 mAb licensed from Panorama Research Inc |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 16)* Corbus Pharmaceuticals Holdings Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 21833P103 (CUSIP Number) May 28, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| June 1, 2021 |
EX-99.2 3 ex99-2.htm Exhibit 99.2 |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Information required in proxy statement schedule 14A information PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Co |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 CORBUS PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37348 46-4348039 (State or other jurisdiction (Commission (IRS E |
|
| May 13, 2021 |
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates Exhibit 99.1 Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates ? Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 ? Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022 ? Corbus is actively engaging with potential partners to expand its pipeline through acquis |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to. |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 15)* Corbus Pharmaceuticals Holdings Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 21833P103 (CUSIP Number) May 10, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| April 6, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| April 6, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| March 26, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14)* Corbus Pharmaceuticals Holdings Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 21833P103 (CUSIP Number) March 16, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de |
|
| March 16, 2021 |
As filed with the Securities and Exchange Commission on March 16, 2021 Registration No. |
|
| March 15, 2021 |
List of Subsidiaries of the Company.* EX-21.1 2 ex21-1.htm Exhibit 21.1 SUSIDIARIES OF CORBUS PHARMACEUTICALS HOLDINGS, INC. Name of Organization Jurisdiction Corbus Pharmaceuticals, Inc. Delaware Corbus International Limited United Kingdom Corbus Pharmaceuticals Australia Pty Ltd Australia |
